Table 4 Stability estimates for CPM within and between sessions stratified by sex for clinical and healthy cohorts
| Â | Â | Females | Males | ||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Clinical cohort | ICC’s for the absolute difference (95% CI) | ICC’s for the percent change (95% CI) | SEM* | MDC* | ICC’s for the absolute difference (95% CI) | ICC’s for the percent change (95% CI) | SEM* | MDC* |
Within session | CPM trial 1-CPM trial 2 (baseline) | 0.63 (0.33-0.80) | 0.57 (0.19-0.78) | 5.83 | 16.16 | 0.49 (0.21-0.67) | 0.39 (0.05-0.61) | 7.33 | 20.32 |
CPM trial 1-CPM trial 2 (3Â months) | 0.75 (0.43-0.89) | 0.73 (0.36-0.89) | 4.25 | 11.78 | 0.58 (0.32-0.73) | 0.41 (-0.03-0.66) | 6.50 | 18.02 | |
| Â | Healthy cohort | ||||||||
Within session | CPM trial 1-CPM trial 2 (day 1) | 0.60 (0.42-0.72) | 0.55 (0.34-0.69) | 7.45 | 20.65 | 0.79 (0.67-0.87) | 0.66 (0.45-0.79) | 4.26 | 11.81 |
CPM trial 1-CPM trial 2 (day 3) | 0.71 (0.57-0.80) | 0.61 (0.42-0.74) | 7.28 | 20.18 | 0.74 (0.58-0.84) | 0.52 (0.22-0.71) | 4.40 | 12.20 | |
CPM trial 1-CPM trial 2 (day 5) | 0.64 (0.47-0.75) | 0.74 (0.61-0.82) | 7.49 | 20.76 | 0.83 (0.73-0.89) | 0.48 (0.13-0.68) | 4.21 | 11.66 | |
Between session | CPM trial 1 (day1)-CPM trial 1 (day3)-CPM trial 1 (day5) | 0.65 (0.51-0.75) | 0.62 (0.47-0.73) | 7.93 | 21.98 | 0.82 (0.73-0.88) | 0.60 (0.40-0.75) | 4.64 | 12.86 |
| Â | CPM trial 2 (day1)-CPM trial 2 (day3)-CPM trial 2 (day5) | 0.63 (0.49-0.74) | 0.61 (0.46-0.73) | 7.15 | 19.82 | 0.82 (0.74-0.88) | 0.58 (0.35-0.74) | 3.32 | 9.20 |